170 results on '"Pragst, Ingo"'
Search Results
2. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
3. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema
4. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
5. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema
6. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
7. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
8. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model
9. Recombinant fusion protein linking factor VIIa with albumin (rVIIaFP): Tissue distribution in rats
10. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII
11. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats
12. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII
13. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
14. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema
15. Medetomidine/midazolam/ketamine anaesthesia in ferrets: effects on cardiorespiratory parameters and evaluation of plasma drug concentrations
16. FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis
17. Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model
18. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models
19. Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
20. Local photodynamic therapy reduces tissue hyperplasia after stenting in an experimental restenosis model
21. Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters
22. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
23. MOESM1 of Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
24. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks
25. Population Pharmacokinetic/Pharmacodynamic Modelling Reveals A Positive Relationship Between Complement 4 Serum Antigen Concentrations And C1 Inhibitor Functional Activity Levels
26. Long-term Safety of Subcutaneous C1-Inhibitor in the Prophylactic Treatment of Hereditary Angioedema
27. Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters.
28. Pharmacokinetic Profile of Subcutaneous C1-Esterase Inhibitor (C1-INH [SC]) in Adolescent and Adult Patients with Hereditary Angioedema (HAE)
29. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks: An Open-Label Extension Study of the COMPACT Trial
30. Risk for Attacks in Hereditary Angioedema (HAE) Population Correlates with C1-inhibitor Functional Activity (C1-INHact)
31. Subcutaneous C1-Esterase Inhibitor [C1-INH(SC)] to Prevent Hereditary Angioedema (HAE) Attacks: Subject and Investigator Assessments from the Compact Trial
32. 1528: 4F-PCC DEMONSTRATES FAVORABLE EFFICACY IN A RABBIT MODEL OF COAGULOPATHY AND ACUTE BLEEDING
33. 1504: 4F-PCC DEMONSTRATES FAVORABLE SAFETY PROFILE IN A RABBIT MODEL OF VENOUS THROMBOSIS
34. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema
35. The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats
36. Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component
37. Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP)
38. Utility of a high VWF
39. Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage
40. C1-esterase inhibitor treatment: preclinical safety aspects on the potential prothrombotic risk
41. A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk
42. Four-Factor Prothrombin Complex Concentrate (4-PCC) Effectively Reverses Edoxaban Induced Bleeding In a Rabbit Model Of Acute Injury
43. Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux
44. Berinert® (C1-Esterase Inhibitor Concentrate) Treatment Is Not Related to Prothrombotic Risk Based On Preclinical Efficacy and Safety Investigations
45. Reconstituted high-density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component.
46. Pre-Clinical Characteristics of a Recombinant Fusion Protein Linking Activated Coagulation Factor VII with Albumin (rVIIa-FP)
47. Biodistribution of the Recombinant Fusion Protein Linking the Human Factor IX to Human Albumin (rIX-FP) in Rats
48. Pharmacodynamic Activity and Preclinical Safety of CSL362, a Novel Humanised, Affinity Matured Monoclonal Antibody Against Human Interleukin 3 Receptor
49. CSL112, A NOVEL FORMULATION OF HUMAN APOA-I, RAPIDLY ACTIVATES LECITHIN-CHOLESTEROL ACYLTRANSFERASE UPON INFUSION INTO RABBITS AND MONKEYS
50. CSL112, A NOVEL FORMULATION OF HUMAN APOA-I, RAPIDLY ENHANCES CHOLESTEROL EFFLUX CAPACITY OF PLASMA FOLLOWING INFUSION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.